The development of a tumor in the early stages of growth is associated with the delivery of nutrients and oxygen to the tumor cells by diffusion from the surrounding healthy tissue, while in the later stages, when the tumor size is so large that it begins to lack oxygen and nutrients, comes to neoangiogenesis - the formation of blood vessels in the area of the affected tissue. Tumor vessels are leaky, winding and have a lot of bottlenecks and dead-ends. Abnormalities of blood vessels anatomy determine the deceleration rate and residual blood flow. Tumor vascularization affects its local growth, and in the case of tumors with the potential to distant metastases, the increase vascularity of tumor by increasing the density of the blood vessel network is directly proportional to the risk of distant metastasis. The aim of the study was to summary the role of the formation of tumor blood vessels in the context of the development of tumors.

tumour vascularization, neoangiogenesis

Rice J. J., Gerwins P., Kilarski W. W. Mechanisms of Angiogenesis: Perspectives from Antiangiogenic Tumor Therapies. Current Angiogenesis, 1(2012), s.139-147.

Battegay E. J. Angiogenesis mechanistic insights, neovascular diseases. Mol Med 73(1995), s. 333-346.

Dvorak H. F. VPF/VEGF and the angiogenic response. Semin Perinatol 24(2000) s.75–78.

Giordano F. J. Angiogenesis: mechanisms, modulation, and targeted imaging. J Nucl Cardiol 6(1999) s. 664-671.

Folkman J., Shing Y. Angiogenesis. J Biol Chem 267(1992) s.10931–10934.

Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1(1995), s. 27-31.

Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 333(1995)

p. 1757-1762.

Carmeliet P., Jain R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473/7347(2011) s. 298-307.

Juczewska M., Chyczewska E., Naumnik W., Niklińska W. Udział komórek tucznych

w angioneogenezie. Postępy Biologii Komórki 27(3)(2000) s. 343-358.

Denekamp J. The tumour microcirculation as a target in cancer therapy: a clearer perspective. Eur J Clin Invest 29(1999) s. 733-736.

Hesselius P., Bergqvist M., Brattström D., Larsson A., Brodin O., Wagenius G. VEGF measured in serum and its correlation to clinical parameters in patients with non-small cell lung cancer. Lung Cancer 29(2000) s. 255.

Fox S.B., Gasparini G., Harris A. L. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol (2001)

p. 278-290.

Kerbel R. S. Tumor angiogenesis: past, present and the near future. Carcinogenesis. 21(2000) s. 505-515.

Reynolds A.R., Hart I.R., Watson A.R., Welti J. C., Silva R.G., Robinson S.D., Da Violante G., Gourlaouen M., Salih M., Jones M. C., Jones D. T., Saunders G., Kostourou V., Perron-Sierra F., Norman J. C., Tucker G. C., Hodivala-Dilke K. M. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med. 15(2009) s. 392-400.

Dvorak H. F. VPF/VEGF and the angiogenic response. Semin Perinatol 24(2000) s.75-78.

Veikkola T. Karkkainen M., Claesson-Welsh L., Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60(2000) s. 203-212.

Liao M., Wang H., Lin Z., Feng J., Zhu D. Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non- small cell lung cancer. Lung Cancer 33(2001) s. 125-132.

Fontanini G., Faviana P., Lucchi M., Boldrini L., Mussi A., Camacci T., Mariani M. A., Angeletti C. A., Basolo F., Pingitore R. A high vascular count and overex-pression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 86(2002) s. 558-563.

Fox S. B., Gasparini G., Harris A. L. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol (2001) s. 278-290.

Kaya A., Ciledag A., Gulbay B. E., Poyraz B. M., Celik G., Sen E., Savas H., Savas I. The prognostic signifi cance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med. 98(2004), s. 632-636.

Park S. H., Lee S. S. The relationship between serum VEGF concentration and prognosis of lung cancer. Korean J Intern Med. 18(2003) p. 207-211.

Krucker T., Lang A., Meyer E. P. New Polyurethane-based material for vascular corrosion casting with improved physical and imaging characteristics. Microsc Res Tech 69(2006), p. 138-147.

Miodoński A. J., Bugajski A., Litwin J. A., Piasecki Z. Vascular architecture of human urinary bladder carcinoma: a SEM study of corrosion casts. Virchows Arch. 433(1998), p. 145-151.

Konerding M. A., Miodoński A. J., Lamatschwandtner A. Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc, 9(4)(1995) s. 1233-1243.

Fukumura D., Duda D. G., Munn L. L., Jain R. K., Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation, 17(3)(2010) s. 206-225.

M. S. O'Reilly, L. Holmgren, Y. Shing, C. Chen, R. A. Rosenthal, M. Moses, W. S. Lane, Y. Cao, E. H. Sage, J. Folkman. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.Cell. 1994 Oct 21; 79(2): 315–328.

Boehm T, Folkman J, Browder T, O’Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404–407.

http://what-when-how.com/acp-medicine/molecular-genetics-of-cancer-part-4/ Retrieved (07.09.2017)

Poon, R. T., Fan, S. T., and Wong, J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. (2001) 19, 1207–1225.

Jain R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307(5706)(2005), s. 58-62.